In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Ann Intern Med
; 175(10): JC115, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-36191322
ABSTRACT
SOURCE CITATION Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4) a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10888-99. 35617986.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Ann Intern Med
Año:
2022
Tipo del documento:
Article